other material
confidence high
sentiment neutral
materiality 0.80
Eledon Phase 2 BESTOW trial: tegoprubart eGFR 69 vs tacrolimus 66, primary endpoint not met but safety superior
Eledon Pharmaceuticals, Inc.
- Primary efficacy endpoint (eGFR at 12 months) did not reach statistical significance: 69 vs 66 mL/min/1.73 m².
- New-onset diabetes 1/47 on tegoprubart vs ~1/6 on tacrolimus; tremor 1.6% vs 25.0%; delayed graft function 14.3% vs 25.0%.
- Efficacy failure composite (death, graft loss, BPAR) was 22% tegoprubart vs 17% tacrolimus, meeting non-inferiority margin.
- Cash, equivalents, and short-term investments approximately $93.4M as of Sept 30, 2025, expected to fund operations to late 2026.
- Company plans to advance tegoprubart into Phase 3 after regulatory discussions on study design and data requirements.